SecBot SecBot

MSLE

Satellos Bioscience Inc.
Nasdaq· Pharmaceutical Preparations· Inc. Z4· CIK 0001421642 Biotech & Drug Discovery
$6.88 +0.34 (+5.20%)
Oct 27 4:00 PM ET · prev $6.54
Market cap
$136.2M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$22.50
+227% · range $16.00–40.00
1 year
+7.2%
from $6.42 · Oct 28
30 days
−21.9%
from $8.81
52-week range
$5.59–13.01
−47% from high · low Apr 7
Avg volume 20D
50.0K
shares / day
Short interest
97.3K
≈0.5% of shares · −8.0%
Days to cover
1.6
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 0 bearish · 4 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/11
Strongest BULLISH Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.677 → −$0.628 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.0% to 97.3K shares. 1.6 days to cover, ≈0.5% of shares.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCTRIM152,768$1.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM150,000$1.2M
CITADEL ADVISORS LLCADD67,738$526.7K
UBS Group AGDOUBLED781$6.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +227%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2026Craig-Hallum
INITIATE
INITIATEBuy
Aug 17, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 9, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Earnings setup

Estimates
−$0.63
EPS estimate, this quarter
+7%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.63-$0.93–-$0.44-1.7%$0.00
Next Q-$0.68-$1.11–-$0.49-6.1%$0.00
Current FY-$2.49-$3.27–-$2.13-5.5%$0.00
Next FY-$2.61-$4.82–-$1.32-4.5%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Press release
🔒 Fresh data, subscribers only
Oct 5, 2026
Press release
Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides…
Sep 30, 2026
FDA
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Data from BASECAMP expected in Q1 2027 Data from BASECAMP expected in Q1 2027
Sep 24, 2026
Contract
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing…
Aug 13, 2026
Earnings
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing…

Short side

FINRA· Oct 15, 2026
97,288
shares short
-8.0%
vs prior settlement
1.6
days to cover
≈0.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 Other
🔒 Fresh data, subscribers only
Oct 21, 2026 SEC
Satellos Bioscience announced management participation in two upcoming investor conferences (Guggenheim Healthcare…
6-K — Impact 2/10
Oct 5, 2026 SEC
Satellos announced the USPTO issued U.S. Patent No. 12,747,245 with composition of matter claims covering its lead…
6-K — Impact 6/10
Sep 30, 2026 Press
Satellos Bioscience completed enrollment for BASECAMP, its Phase 2 trial of forazapadin in Duchenne muscular…
Impact 6/10
Sep 24, 2026 Press
Satellos received FDA clearance for its IND application for forazapadin in FSHD, a second degenerative muscle disease…
Impact 6/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
152,768 shares ($1.2M)
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — TRIM
150,000 shares ($1.2M)

SecBot reports

18 filings · 4 press releases · 6 bullish · 0 bearish · 12 neutral
All MSLE filing & press-release reports (22)